Investors Cushion Indian Stock Market With $4.9 Billion Record Inflows
Good morning, this is Ashutosh Joshi, an equities reporter in Mumbai. Stocks look set to build on Monday's gains, tracking gains across Asia after US President Donald Trump extended the tariff truce with China by 90 days. There's some hope that early signs of a rebound in India's corporate profits and sustained retail flows through mutual funds might keep the mood upbeat. On the institutional side, FPIs seem be trimming short positions even as the broader market still feels directionless. Key earnings to watch today: Oil & Natural Gas Corp. and Hindalco Industries Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
India cenbank committee recommends AI framework for finance sector
By Ashwin Manikandan MUMBAI (Reuters) -A Reserve Bank of India committee has recommended a framework for developing AI capabilities for the country's financial sector, while safeguarding it against associated risks, according to a report released on Wednesday. The committee has recommended setting up a digital infrastructure to help build indigenous AI models and a multi-stakeholder standing committee to evaluate risks and opportunities. It also suggested building a fund to incentivise the development of homegrown AI models tailored for the needs of India's financial services sector. "The report envisions a financial ecosystem where encouraging innovation is in harmony, and not at odds, with mitigation of risk," the RBI said in a statement. The report contains 26 recommendations under six categories including infrastructure, capacity, policy, governance, protection and assurance. Other key recommendations by the eight-member committee headed by Pushpak Bhattacharyya, a computer scientist at IIT Bombay, include issuing of an enabling framework to integrate AI with existing digital public platforms such as instant payment system UPI, and designing audit frameworks. The central bank had set up the committee in December to develop a Framework for Responsible and Ethical Enablement of Artificial Intelligence (FREEAI) for the finance sector. "The challenge with regulating AI is in striking the right balance, making sure that society stands to gain from what this technology has to offer, while mitigating its risks," according to the report. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
2 Stocks Down More Than 90% That Still Aren't Worth Buying
Key Points Teladoc Health and Tilray Brands have lost significant value over the past five years. Teladoc is posting slow growth and consistent net losses, with little hope of a turnaround. Tilray faces several roadblocks in the highly regulated cannabis industry. 10 stocks we like better than Teladoc Health › While basic investing wisdom advises us to "buy low," no point is low enough when there's hardly any hope that a stock will bounce back. In other words, no matter how much a company lags the market, sometimes it still isn't attractive. In my view, that's the case with Teladoc Health (NYSE: TDOC) and Tilray Brands (NASDAQ: TLRY), both of which have lost more than 90% of their market value over the past five years. Their stocks still aren't worth buying, though. Here's what investors need to know about these companies. 1. Teladoc Health Teladoc, a telemedicine specialist, experienced a surge in popularity in 2020, as people were confined to their homes and had limited options for accessing medical care. Patients can access basic consultations, prescriptions, and referrals through telemedicine platforms. Teladoc helped provide that, but the company's fortunes turned in 2021. Demand for its services declined as government-imposed lockdown measures expired. The company also experienced consistent, and sometimes significant, net losses. Furthermore, BetterHelp, Teladoc's virtual therapy service and one of its main growth drivers during this period, also started facing challenges. BetterHelp encountered stiff competition, which ate into its market share. Due to all these issues, Teladoc's revenue has been growing very slowly -- if at all -- for the past few quarters, and the company remains unprofitable. Teladoc is looking to turn things around. One bright spot in the company's recent financial results has been its international expansion efforts. International revenue has been growing at a faster rate than in the rest of its business. If it can continue setting roots in countries outside the U.S., it could exploit meaningful growth opportunities there, or so the argument goes. Since the company's ecosystem remains deep -- with approximately 102 million integrated-care members -- Teladoc also hopes that it can grow revenue by cross-selling additional products to its existing members. While these plans sound good in theory, it's doubtful that Teladoc can pull them off. The telehealth specialist's efforts abroad might increase its already high expenses and make it harder for the company to turn profitable. And while cross-selling more products to existing members might be a great idea, Teladoc has failed to make meaningful progress in the past few years through this route. Maybe the company will eventually turn that around, but there's little reason to believe it will. The stock looks likely to remain southbound for some time, which is why it's best to avoid it. 2. Tilray Brands Tilray is a leader in the cannabis industry. The company offers a suite of products across both recreational and medical channels in Canada, the U.S., Germany, and several other countries. In Canada, Tilray still has the leading market share. However, none of that has allowed the company to perform well in recent years. It's not entirely Tilray's fault, since the cannabis industry faces significant regulatory challenges in the U.S.; the substance remains illegal at the federal level. Even in Canada, where medical and recreational uses of cannabis are legal, there have been challenges for the business, including oversupply. Although Tilray has the leading market share in Canada, the landscape has been challenging enough that it hasn't been able to grow its top and bottom lines consistently. In fairness, Tilray is now a fairly diversified company. It has expanded its craft brewing business, and also purchases and resells various pharmaceutical products in Germany through its distribution segment. The final business unit, "wellness," involves the production and sale of hemp-based foods. That said, diversification has had little impact on improving Tilray's financial results. So the company continues to rely on potential regulatory progress in the cannabis market. CEO Irwin Simon thinks recreational uses of cannabis will be legal in the U.S. by the end of President Donald Trump's second term. That's one reason the company expanded its craft brewing business in the U.S. through acquisition -- so it can sell drinks infused with THC and CBD when that happens. Tilray hopes that once legalization lands, it will be able to hit the ground running and dominate the markets for both recreational cannabis and cannabis-infused drinks, thanks to its existing footprint. However, there's no guarantee that this scenario will materialize anytime soon. While Tilray's shares recently soared on news that Trump could reclassify marijuana from a Schedule I substance to Schedule III, that's some ways away from federal legalization. It would be progress, to be clear. Schedule I drugs are considered to have the highest potential for abuse; that's not the case for Schedule III substances. However, marijuana would remain a controlled substance, still subject to heavy regulations at the federal level. But even under Simon's best-case scenario -- not just rescheduling but full-blown legalization -- we learned from our neighbors to the north that it's no guarantee of success for cannabis players. Tilray could encounter many of the same issues it faced in Canada. These included an initially complicated retail licensing system, stiff competition, and oversupply. In short, there's little hope that Tilray can bounce back anytime soon. The stock isn't worth investing in today. Should you buy stock in Teladoc Health right now? Before you buy stock in Teladoc Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Teladoc Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Teladoc Health. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. 2 Stocks Down More Than 90% That Still Aren't Worth Buying was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
India's Infosys to buy 75% stake in Telstra unit for $153 million
(Reuters) -Indian IT services company Infosys said on Wednesday it would buy a 75% stake in Versent Group, a unit of Australia's Telstra Group, for A$233.3 million ($153 million). ($1 = 1.5279 Australian dollars) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
